In conclusion, in this study, we have demonstrated the in vitro efficacy of UCB-NK cells against multiple CRC cell lines independent of EGFR expression and EGFR downstream signaling mutations, and in addition have demonstrated the in vivo antitumor efficacy of adoptively transferred UCB-NK cells against EGFR+RASmut tumors. This evidence concerns the gene EGFR and colorectal carcinoma.